Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Holtzman

Showing results (1-10 of 602) with videos related to

Pageof 61
Sort By:
Neurobiology of Aging|December 10, 2002
Abeta conformational change is central to Alzheimer's diseaseDavid M Holtzman
Alzheimer Disease and Associated Disorders|June 19, 2003
Amyloid-beta binding molecule: potential role in the pathogenesis and treatment of Alzheimer diseaseDavid M Holtzman
Alzheimer Disease and Associated Disorders|September 27, 2003
Potential role of endogenous and exogenous amyloid-beta binding molecules in the pathogenesis, diagnosis, and treatment of Alzheimer diseaseDavid M Holtzman
Neurobiology of Aging|November 15, 2011
CSF biomarkers for Alzheimer's disease: current utility and potential future useDavid M Holtzman
Nature|July 25, 2008
Alzheimer's disease: Moving towards a vaccineDavid M Holtzman
EMBO Molecular Medicine|January 6, 2010
A surrogate marker for Abeta42 production in the CNSDavid M Holtzman
JAMA|November 4, 2010
Are CSF biomarkers ready for prime time as diagnostics for Alzheimer disease? Interview by Rebecca VoelkerDavid M Holtzman
Archives of Neurology|March 14, 2007
Pittsburgh compound B retention and verification of amyloid depositionDavid M Holtzman
Archives of Neurology|April 25, 2012
CSF biomarkers for secondary prevention trials: why markers of amyloid deposition and neurodegeneration are both importantDavid M Holtzman
Archives of Neurology|December 17, 2009
Cerebrospinal fluid beta-amyloid 42, Tau, and P-tau: confirmation now realizationDavid M Holtzman
Pageof 61

Showing results (1-10 of 602) with videos related to

Sort By:
Pageof 61
Neurobiology of Aging|December 10, 2002
Abeta conformational change is central to Alzheimer's diseaseDavid M Holtzman
Alzheimer Disease and Associated Disorders|June 19, 2003
Amyloid-beta binding molecule: potential role in the pathogenesis and treatment of Alzheimer diseaseDavid M Holtzman
Alzheimer Disease and Associated Disorders|September 27, 2003
Potential role of endogenous and exogenous amyloid-beta binding molecules in the pathogenesis, diagnosis, and treatment of Alzheimer diseaseDavid M Holtzman
Neurobiology of Aging|November 15, 2011
CSF biomarkers for Alzheimer's disease: current utility and potential future useDavid M Holtzman
Nature|July 25, 2008
Alzheimer's disease: Moving towards a vaccineDavid M Holtzman
EMBO Molecular Medicine|January 6, 2010
A surrogate marker for Abeta42 production in the CNSDavid M Holtzman
JAMA|November 4, 2010
Are CSF biomarkers ready for prime time as diagnostics for Alzheimer disease? Interview by Rebecca VoelkerDavid M Holtzman
Archives of Neurology|March 14, 2007
Pittsburgh compound B retention and verification of amyloid depositionDavid M Holtzman
Archives of Neurology|April 25, 2012
CSF biomarkers for secondary prevention trials: why markers of amyloid deposition and neurodegeneration are both importantDavid M Holtzman
Archives of Neurology|December 17, 2009
Cerebrospinal fluid beta-amyloid 42, Tau, and P-tau: confirmation now realizationDavid M Holtzman
Pageof 61